Literature DB >> 30252642

Genetic diversity of hepatitis B virus in Yunnan, China: identification of novel subgenotype C17, an intergenotypic B/I recombinant, and B/C recombinants.

Yue Feng1, Jieyu Ran1, Yue-Mei Feng2, Jing Miao1, Yue Zhao1, Yuanyuan Jia1, Zheng Li3, Wei Yue4, Xueshan Xia1.   

Abstract

Yunnan is considered to be a geographical hotspot for the introduction, mutation and recombination of several viruses in China. However, there are limited data regarding the genotypic profiles of hepatitis B virus (HBV) in this region. In this study, we characterized 206 HBV strains isolated from chronic hepatitis B patients in Yunnan, China. Initial genotyping based on 1.5 kb sequences revealed that genotype C was the most prevalent at 52.4 % (108/206), followed by genotype B at 30.6 % (63/206) and unclassified genotypes at 17.0 % (35/206). To characterize the 35 unclassified strains, 32 complete HBV genomes were amplified and analysed; 17 isolates were classified within a known subgenotype, 8 were classified as B/C recombinants, 1 was classified as a B/I recombinant and 6 constituted a potentially novel C subgenotype that we designated as C17, based on the characteristics of a monophyletic cluster, >4 % genetic distances, no significant evidence of recombination and no epidemiological link among individuals. Thus, multiple subgenotypes - namely B1, B2, B4, C1, C2, C3, C4, C8 and C17 - and two distinct intergenotypic recombinants exist in Yunnan, China, highlighting the complex and diverse distribution pattern of HBV genotypic profiles.

Entities:  

Keywords:  Yunnan; chronic hepatitis B; genetic diversity; genotype and subgenotype; hepatitis B virus

Year:  2020        PMID: 30252642     DOI: 10.1099/jgv.0.001147

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  1 in total

1.  Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.

Authors:  Mousumi Khatun; Krishna Kumar; Ayana Baidya; Rajiv Kumar Mondal; Ondřej Baszczyňski; Filip Kalčic; Soma Banerjee; Gopal Krishna Dhali; Kausik Das; Abhijit Chowdhury; Zlatko Janeba; Saikat Chakrabarti; Simanti Datta
Journal:  J Virol       Date:  2021-11-03       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.